8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 14, 2026·SEC
Harmony Biosciences Holdings, Inc.(HRMY)Earnings, Financials & Key Ratios
HRMY•NASDAQ
12.3× P/E·Price updated Jun 19, 2026
AboutHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.Show more
- Revenue$868M+21.5%
- EBITDA$234M+8.8%
- Net Income$159M+9.1%
- EPS (Diluted)2.71+8.0%
- Gross Margin77.16%-1.2%
- EBITDA Margin26.92%-10.5%
- Operating Margin24%-10.1%
- Net Margin18.27%-10.2%
- ROE20.75%-19.7%
HRMY Key Insights
Harmony Biosciences Holdings, Inc. (HRMY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 25.4%
- ✓FCF machine: 40.1% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 40.3%
- ✓Healthy 5Y average net margin of 22.7%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HRMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HRMY Price & Volume
Harmony Biosciences Holdings, Inc. (HRMY) stock price & volume — 10-year historical chart
Loading chart...
HRMY Growth Metrics
Harmony Biosciences Holdings, Inc. (HRMY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years40.3%
3 Years25.64%
TTM20.71%
Profit CAGR
10 Years-
5 Years-
3 Years-4.37%
TTM-4.65%
EPS CAGR
10 Years-
5 Years-
3 Years-3.01%
TTM-5.34%
Return on Capital
10 Years-10.52%
5 Years26.03%
3 Years26.48%
Last Year22.62%
HRMY Recent Earnings
Harmony Biosciences Holdings, Inc. (HRMY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.55-27.6%
$0.76
Rev
$215M-2.5%
$221M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.38-54.8%
$0.84
Rev
$244M+1.4%
$240M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.87-5.4%
$0.92
Rev
$239M-0.2%
$240M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.68-12.8%
$0.78
Rev
$200M-8.9%
$220M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.55vs $0.76-27.6% | $215Mvs $221M-2.5% |
| Q1 2026 | Feb 24, 2026 | $0.38vs $0.84-54.8% | $244Mvs $240M+1.4% |
| Q4 2025 | Nov 4, 2025 | $0.87vs $0.92-5.4% | $239Mvs $240M-0.2% |
| Q3 2025 | Aug 5, 2025 | $0.68vs $0.78-12.8% | $200Mvs $220M-8.9% |
Based on last 12 quarters of dataView full earnings history →
HRMY Peer Comparison
Harmony Biosciences Holdings, Inc. (HRMY) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 | |
 AVPT | 2.21B | 10.41 | 69.40 | 26.93% | 10.51% | 10.2% | 0.02 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% |
Compare HRMY vs Peers
Harmony Biosciences Holdings, Inc. (HRMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HRMY Income Statement
Harmony Biosciences Holdings, Inc. (HRMY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 6M | 159.74M | 305.44M | 437.86M | 582.02M | 714.73M | 868.45M | 899.11M |
Revenue Growth % | - | - | 2564.59% | 91.21% | 43.35% | 32.93% | 22.8% | 21.51% | 20.71% |
Cost of Goods Sold | 184K | 1.58M | 27.74M | 55.52M | 83.48M | 121.24M | 156.81M | 198.34M | 210.86M |
COGS % of Revenue | - | 26.31% | 17.36% | 18.18% | 19.07% | 20.83% | 21.94% | 22.84% | - |
Gross Profit | -184K▲ 0% | 4.42M▲ 2501.1% | 132M▲ 2887.9% | 249.92M▲ 89.3% | 354.37M▲ 41.8% | 460.79M▲ 30.0% | 557.92M▲ 21.1% | 670.11M▲ 20.1% | 688.25M▲ 0% |
Gross Margin % | - | 73.69% | 82.64% | 81.82% | 80.93% | 79.17% | 78.06% | 77.16% | 76.55% |
Gross Profit Growth % | - | 2501.09% | 2887.87% | 89.33% | 41.79% | 30.03% | 21.08% | 20.11% | - |
Operating Expenses | 41.44M | 150.32M | 115.02M | 162.39M | 234.19M | 268.76M | 367.09M | 461.64M | 498.73M |
OpEx % of Revenue | - | 2507.46% | 72% | 53.17% | 53.49% | 46.18% | 51.36% | 53.16% | - |
Selling, General & Admin | 29.07M | 80.73M | 95.57M | 132.03M | 163.3M | 192.69M | 221.27M | 272.05M | 274.3M |
SG&A % of Revenue | - | 1346.57% | 59.83% | 43.23% | 37.3% | 33.11% | 30.96% | 31.33% | - |
Research & Development | 12.37M | 69.59M | 19.45M | 30.37M | 70.89M | 76.06M | 145.82M | 189.59M | 224.44M |
R&D % of Revenue | - | 1160.88% | 12.17% | 9.94% | 16.19% | 13.07% | 20.4% | 21.83% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -41.44M▲ 0% | -145.9M▼ 252.1% | 16.99M▲ 111.6% | 87.53M▲ 415.3% | 120.19M▲ 37.3% | 192.03M▲ 59.8% | 190.83M▼ 0.6% | 208.47M▲ 9.2% | 189.51M▲ 0% |
Operating Margin % | - | -2433.76% | 10.63% | 28.66% | 27.45% | 32.99% | 26.7% | 24% | 21.08% |
Operating Income Growth % | - | -252.09% | 111.64% | 415.29% | 37.31% | 59.78% | -0.63% | 9.25% | - |
EBITDA | -41.26M | -142.69M | 27.22M | 106.37M | 143.57M | 216.39M | 214.94M | 233.8M | 214.85M |
EBITDA Margin % | - | -2380.22% | 17.04% | 34.82% | 32.79% | 37.18% | 30.07% | 26.92% | 23.9% |
EBITDA Growth % | - | -245.88% | 119.08% | 290.73% | 34.98% | 50.72% | -0.67% | 8.78% | -1.89% |
D&A (Non-Cash Add-back) | 184K | 3.21M | 10.24M | 18.84M | 23.39M | 24.36M | 24.11M | 25.34M | 25.34M |
EBIT | -41.44M | -145.9M | -8.72M | 61.62M | 123.48M | 197.15M | 209.3M | 229.71M | 208M |
Net Interest Income | 0 | -6.07M | -28.22M | -23.97M | -15.67M | -9.03M | 1.05M | 7.28M | 8.59M |
Interest Income | 0 | 0 | 0 | 224K | 3.13M | 14.73M | 18.54M | 21.92M | 22.64M |
Interest Expense | 0 | 6.07M | 28.22M | 24.19M | 18.8M | 23.76M | 17.5M | 14.65M | 14.05M |
Other Income/Expense | 1.54M | -6.07M | -53.93M | -50.1M | -15.5M | -18.63M | 978K | 6.59M | 8.06M |
Pretax Income | -39.9M▲ 0% | -151.98M▼ 280.9% | -36.94M▲ 75.7% | 37.43M▲ 201.3% | 104.69M▲ 179.7% | 173.4M▲ 65.6% | 191.8M▲ 10.6% | 215.06M▲ 12.1% | 197.57M▲ 0% |
Pretax Margin % | - | -2535.06% | -23.13% | 12.25% | 23.91% | 29.79% | 26.84% | 24.76% | 21.97% |
Income Tax | 0 | 0 | 0 | 2.83M | -76.78M | 44.54M | 46.31M | 56.38M | 51.96M |
Effective Tax Rate % | 0% | 0% | 0% | 7.56% | -73.35% | 25.69% | 24.14% | 26.21% | 26.3% |
Net Income | -39.9M▲ 0% | -151.98M▼ 280.9% | -36.94M▲ 75.7% | 34.6M▲ 193.6% | 181.47M▲ 424.5% | 128.85M▼ 29.0% | 145.49M▲ 12.9% | 158.69M▲ 9.1% | 145.62M▲ 0% |
Net Margin % | - | -2535.06% | -23.13% | 11.33% | 41.44% | 22.14% | 20.36% | 18.27% | 16.2% |
Net Income Growth % | - | -280.91% | 75.69% | 193.65% | 424.52% | -28.99% | 12.91% | 9.07% | -4.65% |
Net Income (Continuing) | -39.9M | -151.98M | -36.94M | 34.6M | 181.47M | 128.85M | 145.49M | 158.69M | 145.62M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.42▲ 0% | -2.94▼ 107.0% | -1.10▲ 62.6% | 0.58▲ 152.7% | 2.97▲ 412.1% | 2.13▼ 28.3% | 2.51▲ 17.8% | 2.71▲ 8.0% | 2.48▲ 0% |
EPS Growth % | - | -107.04% | 62.59% | 152.73% | 412.07% | -28.28% | 17.84% | 7.97% | -5.34% |
EPS (Basic) | -1.42 | -2.94 | -1.12 | 0.60 | 3.07 | 2.17 | 2.56 | 2.76 | - |
Diluted Shares Outstanding | 49.24M | 63.68M | 57.85M | 59.21M | 61.1M | 60.37M | 57.87M | 58.54M | 58.78M |
Basic Shares Outstanding | 49.24M | 63.68M | 56.89M | 57.53M | 59.17M | 59.47M | 56.88M | 57.49M | 57.82M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
HRMY Balance Sheet
Harmony Biosciences Holdings, Inc. (HRMY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 86.68M | 31.5M | 262.89M | 284.44M | 400.29M | 451.07M | 579.25M | 907.01M | 778.82M |
Cash & Short-Term Investments | 83.52M | 24.46M | 228.63M | 234.31M | 323.12M | 353.46M | 467.19M | 775.34M | 640.92M |
Cash Only | 83.52M | 24.46M | 228.63M | 234.31M | 243.78M | 311.66M | 453M | 752.5M | 589.4M |
Short-Term Investments | 0 | 0 | 0 | 0 | 79.33M | 41.8M | 14.19M | 22.84M | 51.52M |
Accounts Receivable | 0 | 4.25M | 22.18M | 34.84M | 54.74M | 74.14M | 83.03M | 96.79M | 108.22M |
Days Sales Outstanding | - | 259.06 | 50.67 | 41.64 | 45.63 | 46.49 | 42.4 | 40.68 | 40.46 |
Inventory | 0 | 1.09M | 3.82M | 4.43M | 4.3M | 5.36M | 7.2M | 5.36M | 5.28M |
Days Inventory Outstanding | - | 251.82 | 50.31 | 29.14 | 18.79 | 16.15 | 16.75 | 9.86 | 10.22 |
Other Current Assets | 2.46M | 261K | 1.3M | 3.22M | 8.79M | 5.54M | 8.12M | 13.52M | 7.59M |
Total Non-Current Assets | 2.6M | 75.21M | 164.18M | 149M | 273.58M | 360.38M | 419.95M | 364.62M | 493.01M |
Property, Plant & Equipment | 1.58M | 1.33M | 938K | 4.12M | 573K | 371K | 3.38M | 5.34M | 5.39M |
Fixed Asset Turnover | - | 4.51x | 170.30x | 74.17x | 764.14x | 1568.79x | 211.52x | 162.51x | 224.03x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 72.19M | 162.34M | 143.92M | 160.95M | 137.11M | 113.26M | 89.42M | 83.46M |
Long-Term Investments | 500K | 0 | 0 | 0 | 22.57M | 72.17M | 108.87M | 107.4M | 550.06M |
Other Non-Current Assets | 522K | 1.69M | 902K | 967K | 3.55M | 6.57M | 194.43M | 12.76M | 20.77M |
Total Assets | 89.28M▲ 0% | 106.7M▲ 19.5% | 427.07M▲ 300.2% | 433.44M▲ 1.5% | 673.87M▲ 55.5% | 811.45M▲ 20.4% | 999.2M▲ 23.1% | 1.27B▲ 27.3% | 1.27B▲ 0% |
Asset Turnover | - | 0.06x | 0.37x | 0.70x | 0.65x | 0.72x | 0.72x | 0.68x | 0.74x |
Asset Growth % | - | 19.51% | 300.25% | 1.49% | 55.47% | 20.42% | 23.14% | 27.26% | 107.01% |
Total Current Liabilities | 7.23M | 19.89M | 134.54M | 53.77M | 78.88M | 163.78M | 175.08M | 252.13M | 217.34M |
Accounts Payable | 1.46M | 6.36M | 2.56M | 1M | 3.79M | 17.73M | 13.74M | 17.69M | 28.6M |
Days Payables Outstanding | 2.9K | 1.47K | 33.63 | 6.58 | 16.55 | 53.38 | 31.99 | 32.56 | 43.68 |
Short-Term Debt | 0 | 0 | 0 | 2M | 2M | 15M | 16.25M | 86.89M | 63.17M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 313K | 753K | 100.31M | 1 | 1.62M | 107.3M | 4.35M | 129.1M | 118.84M |
Current Ratio | 11.99x | 1.58x | 1.95x | 5.29x | 5.07x | 2.75x | 3.31x | 3.60x | 3.58x |
Quick Ratio | 11.99x | 1.53x | 1.93x | 5.21x | 5.02x | 2.72x | 3.27x | 3.58x | 3.56x |
Cash Conversion Cycle | - | -961.15 | 67.34 | 64.19 | 47.87 | 9.26 | 27.17 | 17.98 | 7 |
Total Non-Current Liabilities | 523K | 98.4M | 195.35M | 193.16M | 192.15M | 180.68M | 164.96M | 149.28M | 144.13M |
Long-Term Debt | 324.2M | 97.95M | 194.25M | 189.98M | 189.65M | 178.57M | 163.02M | 148.18M | 138.81M |
Capital Lease Obligations | 0 | 0 | 0 | 2.4M | 0 | 0 | 822K | 4.51M | 9.88M |
Deferred Tax Liabilities | -324.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -323.68M | 450K | 1.1M | 777K | 2.5M | 2.11M | 1.13M | -3.41M | 793K |
Total Liabilities | 7.75M | 118.29M | 329.89M | 246.94M | 271.03M | 344.46M | 340.05M | 401.41M | 361.48M |
Total Debt | 324.2M | 97.95M | 194.25M | 195.74M | 191.65M | 193.57M | 181.41M | 239.58M | 206.51M |
Net Debt | 240.68M | 73.49M | -34.38M | -38.56M | -52.14M | -118.09M | -271.6M | -512.92M | -382.88M |
Debt / Equity | 3.98x | - | 2.00x | 1.05x | 0.48x | 0.41x | 0.28x | 0.28x | 0.23x |
Debt / EBITDA | - | - | 7.14x | 1.84x | 1.33x | 0.89x | 0.84x | 1.02x | 0.96x |
Net Debt / EBITDA | - | - | -1.26x | -0.36x | -0.36x | -0.55x | -1.26x | -2.19x | -1.78x |
Interest Coverage | - | -24.03x | -0.31x | 2.55x | 6.57x | 8.30x | 11.96x | 15.68x | 14.81x |
Total Equity | 81.53M▲ 0% | -11.59M▼ 114.2% | 97.18M▲ 938.8% | 186.51M▲ 91.9% | 402.84M▲ 116.0% | 466.99M▲ 15.9% | 659.15M▲ 41.1% | 870.22M▲ 32.0% | 910.35M▲ 0% |
Equity Growth % | - | -114.21% | 938.84% | 91.92% | 115.99% | 15.93% | 41.15% | 32.02% | 141.84% |
Book Value per Share | 1.66 | -0.18 | 1.68 | 3.15 | 6.59 | 7.74 | 11.39 | 14.86 | 15.49 |
Total Shareholders' Equity | 81.53M | -11.59M | 97.18M | 186.51M | 402.84M | 466.99M | 659.15M | 870.22M | 910.35M |
Common Stock | 1K | 0 | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -242.67M | -422.86M | -488.19M | -453.6M | -272.13M | -143.28M | 2.22M | 160.9M | 193.39M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2K | 0 | 0 | 0 | -151K | 2K | 66K | 346K | -413K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HRMY Cash Flow Statement
Harmony Biosciences Holdings, Inc. (HRMY) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -38.8M | -75.44M | -2.98M | 98.56M | 144.47M | 219.39M | 219.82M | 348.2M | 341.97M |
Operating CF Margin % | - | -1258.32% | -1.87% | 32.27% | 32.99% | 37.69% | 30.76% | 40.09% | - |
Operating CF Growth % | - | -94.43% | 96.04% | 3401.74% | 46.58% | 51.86% | 0.2% | 58.4% | 189% |
Net Income | -39.9M | -151.98M | -36.94M | 34.6M | 181.47M | 128.85M | 145.49M | 158.69M | 145.62M |
Depreciation & Amortization | 184K | 3.8M | 10.24M | 21.08M | 25.05M | 24.36M | 24.11M | 25.34M | 25.5M |
Stock-Based Compensation | 1.08M | 9.91M | 4.69M | 16.11M | 26.91M | 31.7M | 42.6M | 44.9M | 32.45M |
Deferred Taxes | 0 | 0 | 25.75M | 0 | 0 | -13.42M | -29.3M | 0 | 4.33M |
Other Non-Cash Items | 2.06M | 59.44M | 4.91M | 24.59M | -82.06M | 12.85M | 44.23M | 27.46M | 64.08M |
Working Capital Changes | -164K | 3.39M | -11.63M | 2.19M | -6.89M | 35.03M | -7.32M | 91.82M | 70.01M |
Change in Receivables | 0 | -4.25M | -17.92M | -12.67M | -19.9M | -19.4M | -8.89M | -13.75M | -2.25M |
Change in Inventory | 0 | -1.09M | -2.73M | -609K | 135K | -1.07M | -1.83M | 1.84M | 1.1M |
Change in Payables | -610K | 0 | -3.8M | 0 | 0 | 8.95M | -5.38M | 3.95M | 13.1M |
Cash from Investing | -1.34M | -127.15M | -2M | -100.3M | -141.83M | -46.44M | -67.48M | -39.65M | -225.66M |
Capital Expenditures | -1.34M | -149K | -2M | -298K | -172K | -312K | -1.15M | -19.56M | -19.43M |
CapEx % of Revenue | - | 2.49% | 1.25% | 0.1% | 0.04% | 0.05% | 0.16% | 2.25% | 2.16% |
Acquisitions | 0 | 0 | -2M | 0 | 0 | -36.97M | -33.07M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -127M | 2M | -100M | -141.66M | 0 | -26.5M | -15M | -51.72M |
Cash from Financing | 21.61M | 143.77M | 209.16M | 7.42M | 6.84M | -105.55M | -11M | -9.05M | -15.91M |
Debt Issued (Net) | 0 | 100M | 79.42M | -500K | -2M | -1.25M | -15M | -16.25M | -17.5M |
Equity Issued (Net) | 21.8M | 0 | -184K | 0 | 0 | -100.51M | 6.5M | 10.21M | 5.85M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -3.2M | 0 | -167K | 0 | 0 | -100M | 0 | 0 | 0 |
Other Financing | -185K | 43.77M | 129.93M | 7.92M | 8.84M | -3.79M | -2.5M | -3M | -4.26M |
Net Change in Cash | -18.53M▲ 0% | -58.82M▼ 217.5% | 204.17M▲ 447.1% | 5.68M▼ 97.2% | 9.47M▲ 66.9% | 67.4M▲ 611.3% | 141.34M▲ 109.7% | 299.5M▲ 111.9% | 100.4M▲ 0% |
Free Cash Flow | -40.14M▲ 0% | -75.58M▼ 88.3% | -4.99M▲ 93.4% | 98.26M▲ 2070.3% | 144.29M▲ 46.9% | 219.07M▲ 51.8% | 218.67M▼ 0.2% | 347.89M▲ 59.1% | 341.79M▲ 0% |
FCF Margin % | - | -1260.8% | -3.12% | 32.17% | 32.95% | 37.64% | 30.59% | 40.06% | 38.01% |
FCF Growth % | - | -88.3% | 93.4% | 2070.3% | 46.85% | 51.83% | -0.19% | 59.09% | 54.38% |
FCF per Share | -0.82 | -1.19 | -0.09 | 1.66 | 2.36 | 3.63 | 3.78 | 5.94 | 5.82 |
FCF Conversion (FCF/Net Income) | 0.97x | 0.50x | 0.08x | 2.85x | 0.80x | 1.70x | 1.51x | 2.19x | 2.35x |
Interest Paid | 0 | 4.23M | 0 | 19.83M | 16.36M | 20.05M | 17.32M | 0 | 6.97M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 48.23M | 79.64M | 0 | 35.43M |
HRMY Key Ratios
Harmony Biosciences Holdings, Inc. (HRMY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -434.57% | -86.32% | 24.39% | 61.58% | 29.63% | 25.84% | 20.75% | 17.19% |
Return on Invested Capital (ROIC) | -56.98% | 20.43% | 62.3% | 36.15% | 41.17% | 38.87% | 41.98% | 34.6% |
Gross Margin | 73.69% | 82.64% | 81.82% | 80.93% | 79.17% | 78.06% | 77.16% | 76.55% |
Net Margin | -2535.06% | -23.13% | 11.33% | 41.44% | 22.14% | 20.36% | 18.27% | 16.2% |
Debt / Equity | - | 2.00x | 1.05x | 0.48x | 0.41x | 0.28x | 0.28x | 0.23x |
Interest Coverage | -24.03x | -0.31x | 2.55x | 6.57x | 8.30x | 11.96x | 15.68x | 14.81x |
FCF Conversion | 0.50x | 0.08x | 2.85x | 0.80x | 1.70x | 1.51x | 2.19x | 2.35x |
Revenue Growth | - | 2564.59% | 91.21% | 43.35% | 32.93% | 22.8% | 21.51% | 20.71% |
Related:HRMY Dividend History·HRMY Revenue History·HRMY Price History·HRMY P/E History·HRMY Financial Ratios·HRMY Institutional Holders
HRMY SEC Filings & Documents
Harmony Biosciences Holdings, Inc. (HRMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
HRMY Frequently Asked Questions
Harmony Biosciences Holdings, Inc. (HRMY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Harmony Biosciences Holdings, Inc. (HRMY) reported $899.1M in revenue for fiscal year 2025.
Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 21.5% over the past year. This is strong growth.
Yes, Harmony Biosciences Holdings, Inc. (HRMY) is profitable, generating $145.6M in net income for fiscal year 2025 (18.3% net margin).
Dividend & Returns
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity (ROE) of 20.8%. This is excellent, indicating efficient use of shareholder capital.
Harmony Biosciences Holdings, Inc. (HRMY) generated $341.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.